Brighton Jones LLC Invests $221,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Brighton Jones LLC bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,816 shares of the medical equipment provider’s stock, valued at approximately $221,000.

A number of other institutional investors also recently modified their holdings of the company. American Century Companies Inc. boosted its holdings in shares of Zimmer Biomet by 21.2% during the third quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock worth $545,809,000 after purchasing an additional 852,186 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of Zimmer Biomet by 4.9% during the third quarter. Victory Capital Management Inc. now owns 3,080,463 shares of the medical equipment provider’s stock worth $345,690,000 after purchasing an additional 144,147 shares during the period. Van ECK Associates Corp boosted its holdings in shares of Zimmer Biomet by 23.7% during the fourth quarter. Van ECK Associates Corp now owns 2,838,558 shares of the medical equipment provider’s stock worth $345,452,000 after purchasing an additional 543,344 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of Zimmer Biomet by 16.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,760,021 shares of the medical equipment provider’s stock worth $335,895,000 after purchasing an additional 386,019 shares during the period. Finally, Boston Partners lifted its holdings in Zimmer Biomet by 29.2% in the third quarter. Boston Partners now owns 2,694,832 shares of the medical equipment provider’s stock worth $302,366,000 after buying an additional 608,959 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.95% of the stock is currently owned by insiders.

Zimmer Biomet Price Performance

Shares of ZBH opened at $121.68 on Friday. The company has a market capitalization of $25.00 billion, a P/E ratio of 26.34, a price-to-earnings-growth ratio of 2.17 and a beta of 1.03. The company has a quick ratio of 0.78, a current ratio of 1.66 and a debt-to-equity ratio of 0.38. The firm has a 50 day moving average of $125.45 and a 200 day moving average of $119.90. Zimmer Biomet Holdings, Inc. has a twelve month low of $102.00 and a twelve month high of $147.50.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.07. The company had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.89 earnings per share. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.08 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date of this dividend was Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Analysts Set New Price Targets

ZBH has been the subject of several research analyst reports. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Thursday. TheStreet upgraded shares of Zimmer Biomet from a “c” rating to a “b-” rating in a report on Thursday, February 8th. Barclays raised their price objective on shares of Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a report on Monday, February 12th. Evercore ISI raised their price objective on shares of Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, February 9th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and an average target price of $135.40.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.